Abliva - KL1333 ready for pivotal Phase II/III trial
Just a few months in, Abliva’s new CEO has already spearheaded a successful private placement (SEK80m gross in March 2021), which will now support the preparations for the pivotal KL1333 trial in primary mitochondrial diseases (PMDs). The R&D plan is focused on a single randomised, placebo-controlled Phase II/III trial with an adaptive design, which should start in H221. The newly released clinical dataset from the Phase Ia/b study also support such a strategy. The Phase II/III trial is envisioned undergo an interim futility analysis in H222 and the final results should be available by end-2023. Abliva’s second lead asset NV354, a succinate prodrug for complex I disorders, should complete preclinical development this year. Our valuation is SEK1.21bn or SEK3.01 per share.NeuroVive Pharmaceutical is engaged in the conducting research and development into pharmaceuticals that protect the mitochondria and pharmaceuticals to promote more effective mitochondrial function. The drug development technology platform is cyclosporine A, versions of cyclosporine, and molecules with a similar structure, which together, constitute a new class of pharmaceutical called cyclophilin inhibitors. The project portfolio also includes drug candidates for cellular energy regulation.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.